NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News $99.25 -0.17 (-0.17%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$99.22▼$99.9750-Day Range$96.34▼$112.3852-Week Range$57.84▼$113.83Volume2.66 million shsAverage Volume3.19 million shsMarket Capitalization$22.69 billionP/E Ratio62.42Dividend YieldN/APrice Target$111.42 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Horizon Therapeutics Public MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside12.3% Upside$111.42 Price TargetShort InterestHealthy3.04% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.44Based on 11 Articles This WeekInsider TradingN/AProj. Earnings Growth38.05%From $4.81 to $6.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector232nd out of 988 stocksPharmaceutical Preparations Industry102nd out of 480 stocks 2.1 Analyst's Opinion Consensus RatingHorizon Therapeutics Public has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.42, Horizon Therapeutics Public has a forecasted upside of 12.3% from its current price of $99.25.Amount of Analyst CoverageHorizon Therapeutics Public has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.04% of the outstanding shares of Horizon Therapeutics Public have been sold short.Short Interest Ratio / Days to CoverHorizon Therapeutics Public has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Horizon Therapeutics Public has recently increased by 5.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHorizon Therapeutics Public has received a 34.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Nonsteroidal anti-inflammatory drugs", "Pegloticase", "Cysteamine", "Sodium phenylbutyrate", and "Inebilizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Horizon Therapeutics Public is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentHorizon Therapeutics Public has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Horizon Therapeutics Public this week, compared to 5 articles on an average week.Search InterestOnly 24 people have searched for HZNP on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows8 people have added Horizon Therapeutics Public to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions91.01% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 38.05% in the coming year, from $4.81 to $6.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 62.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 62.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.48.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 2.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Horizon Therapeutics Public (NASDAQ:HZNP) StockHorizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.Read More Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Stock News HeadlinesMay 30, 2023 | marketbeat.com3 Stocks Worth Buying at 52-Week Lows (HZNP)Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investorsJune 9, 2023 | americanbankingnews.comHorizon Therapeutics Public Sees Unusually High Options Volume (NASDAQ:HZNP)June 10, 2023 | Behind the Markets (Ad)WARNING to all American InvestorsChina's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>June 7, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Receives New Coverage from Analysts at StockNews.comJune 6, 2023 | markets.businessinsider.comHorizon Therapeutics And KPMG Women's Irish Open Form Exclusive PartnershipJune 6, 2023 | finance.yahoo.comHorizon Therapeutics plc announces premium partnership with KPMG Women’s Irish OpenJune 5, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual MeetingJune 3, 2023 | finance.yahoo.comHZNP - Horizon Therapeutics Public Limited CompanyJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 1, 2023 | finance.yahoo.comBiomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)May 31, 2023 | finance.yahoo.comNew Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of RheumatologyMay 31, 2023 | finance.yahoo.comPresentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s SyndromeMay 30, 2023 | seekingalpha.comTop Merger Stocks Held By Fund Managers, Mid-Q2 2023May 30, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Research Coverage Started at StockNews.comMay 29, 2023 | americanbankingnews.comAnalysts Set Horizon Therapeutics Public Limited (NASDAQ:HZNP) Target Price at $111.00May 23, 2023 | benzinga.comLooking At Horizon Therapeutics's Recent Unusual Options ActivityMay 23, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of RheumatologyMay 23, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Now Covered by StockNews.comMay 20, 2023 | americanbankingnews.comInvestors Purchase Large Volume of Horizon Therapeutics Public Call Options (NASDAQ:HZNP)May 19, 2023 | americanbankingnews.comHorizon Therapeutics Public (NASDAQ:HZNP) Sees Unusually-High Trading VolumeMay 17, 2023 | msn.comHorizon Therapeutics Unusual Options Activity For May 16May 17, 2023 | finance.yahoo.comFed, labor market concerns showing 'some dents in the armor of the consumer': StrategistMay 17, 2023 | fool.comWhy Horizon Therapeutics Stock Is Crashing TodayMay 17, 2023 | markets.businessinsider.comJefferies Sticks to Its Buy Rating for Horizon Therapeutics (HZNP)May 16, 2023 | finance.yahoo.comHorizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by AmgenMay 16, 2023 | finance.yahoo.comFTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon TherapeuticsMay 16, 2023 | markets.businessinsider.comPre-market Movers: GDC, ELOX, VOXX, HZNP, CALT…See More Headlines HZNP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HZNP Company Calendar Last Earnings5/03/2023Today6/10/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Price Target and Rating Average Stock Price Forecast$111.42 High Stock Price Forecast$144.00 Low Stock Price Forecast$71.00 Forecasted Upside/Downside+12.3%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$1.59 Trailing P/E Ratio62.42 Forward P/E Ratio20.63 P/E Growth2.95Net Income$521.48 million Net Margins10.40% Pretax Margin10.44% Return on Equity20.31% Return on Assets11.37% Debt Debt-to-Equity Ratio0.50 Current Ratio4.07 Quick Ratio3.89 Sales & Book Value Annual Sales$3.63 billion Price / Sales6.25 Cash Flow$7.04 per share Price / Cash Flow14.10 Book Value$22.38 per share Price / Book4.43Miscellaneous Outstanding Shares228,620,000Free Float222,906,000Market Cap$22.69 billion OptionableOptionable Beta1.12 Social Links Key ExecutivesTimothy P. WalbertChairman, President & Chief Executive OfficerAaron L. CoxChief Financial Officer & Executive Vice PresidentJeffrey W. ShermanChief Medical Officer & Executive Vice PresidentVikram KarnaniPresident-International, Medical Affairs & EVPMichael A. DesJardinExecutive VP-Technical Operations & QualityKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZZoetisNYSE:ZTSBeiGeneNASDAQ:BGNEAlnylam PharmaceuticalsNASDAQ:ALNYGenmab A/SNASDAQ:GMABView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 71,596 shares on 6/1/2023Ownership: 0.067%Searle & CO.Sold 1,106 shares on 6/1/2023Ownership: 0.010%Macquarie Group Ltd.Sold 79,685 shares on 6/1/2023Ownership: 0.004%ProShare Advisors LLCSold 3,255 shares on 5/26/2023Ownership: 0.008%Brandywine Global Investment Management LLCSold 310,344 shares on 5/25/2023Ownership: 0.096%View All Insider TransactionsView All Institutional Transactions HZNP Stock - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. What is Horizon Therapeutics Public's stock price forecast for 2023? 11 Wall Street research analysts have issued 1 year target prices for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they anticipate the company's stock price to reach $111.42 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts. How have HZNP shares performed in 2023? Horizon Therapeutics Public's stock was trading at $113.80 at the beginning of 2023. Since then, HZNP stock has decreased by 12.8% and is now trading at $99.25. View the best growth stocks for 2023 here. When is Horizon Therapeutics Public's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our HZNP earnings forecast. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.34. The biopharmaceutical company had revenue of $832.10 million for the quarter, compared to the consensus estimate of $897.06 million. Horizon Therapeutics Public had a net margin of 10.40% and a trailing twelve-month return on equity of 20.31%. The business's revenue was down 6.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.34 earnings per share. What ETFs hold Horizon Therapeutics Public's stock? ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), IQ Merger Arbitrage ETF (MNA), Pinnacle Focused Opportunities ETF (FCUS), AltShares Event-Driven ET (EVNT), Invesco Dynamic Pharmaceuticals ETF (PJP), Subversive Mental Health ETF (SANE) and VictoryShares Nasdaq Next 50 ETF (QQQN). What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). What is Horizon Therapeutics Public's stock symbol? Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.53%), JPMorgan Chase & Co. (2.40%), Farallon Capital Management LLC (2.37%), State Street Corp (2.24%), Renaissance Technologies LLC (1.47%) and Geode Capital Management LLC (1.39%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel. View institutional ownership trends. How do I buy shares of Horizon Therapeutics Public? Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Horizon Therapeutics Public's stock price today? One share of HZNP stock can currently be purchased for approximately $99.25. How much money does Horizon Therapeutics Public make? Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $22.69 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.59 on an earnings per share basis. How many employees does Horizon Therapeutics Public have? The company employs 2,115 workers across the globe. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More How can I contact Horizon Therapeutics Public? Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001. This page (NASDAQ:HZNP) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.